Agios Pharmaceuticals Dividend

Dividend criteria checks 0/6

Agios Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$6.21
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21

Agios Pharmaceuticals: A Near-Term Capital Gain Prospect Seen By Market-Makers As Underpriced

Sep 07

Agios submits mitapivat application in U.S. for pyruvate kinase deficiency

Jun 21

Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

May 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AGIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGIO's dividend payments have been increasing.

Dividend Yield vs Market

Agios Pharmaceuticals Dividend Yield vs Market

How does AGIO dividend yield compare to the market?
Segment	Dividend Yield
Company (AGIO)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (AGIO)	0%

Notable Dividend: Unable to evaluate AGIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AGIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AGIO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AGIO has not reported any payouts.

Agios Pharmaceuticals Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Chair of the Board of Directors exercised options and sold US$215k worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 46%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Consensus revenue estimates fall by 43%

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Chair of the Board of Directors exercised options and sold US$232k worth of stock

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

CEO & Director exercised options and sold US$277k worth of stock

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

CEO & Director exercised options and sold US$325k worth of stock

Agios Pharmaceuticals, Inc. Announces Board Changes

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Director exercised options and sold US$226k worth of stock

Director exercised options and sold US$262k worth of stock

Director exercised options and sold US$269k worth of stock

Director exercised options and sold US$326k worth of stock

Chair of the Board of Directors exercised options and sold US$105k worth of stock

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Director exercised options and sold US$406k worth of stock

Director notifies of intention to sell stock

Insider exercised options and sold US$79k worth of stock

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Price target decreased to US$36.20

Price target increased to US$39.20

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Consensus forecasts updated

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios adds more than 13% after Novo deal to acquire rival Forma

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Agios Pharmaceuticals appoints new board chair, CEO

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Consensus forecasts updated

Agios: Approved Product, Upcoming Catalysts

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Price target decreased to US$41.17

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Price target decreased to US$44.83

Price target increased to US$60.57

CEO & Director exercised options and sold US$107k worth of stock

Agios Pharmaceuticals With FDA Approval Is A Buy

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

CEO & Director exercised options and sold US$107k worth of stock

Agios Before The February PDUFA

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Price target decreased to US$54.86